Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel

Shiota Masaki; Nakamura Motonobu; Yokomizo Akira; Tomoda Toshihisa; Sakamoto Naotaka; Seki Narihito; Hasegawa Shuji; Yunoki Takakazu; Harano Masahiko; Kuroiwa Kentaro; Eto Masatoshi

首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel

【24h】

Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel

机译：先前雄激素受体轴靶向剂在Cabazitaxel化疗后的预后影响多西紫杉醇

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background/ Aim: The novel taxane cabazitaxel has been shown to exert excellent anticancer effects after androgen receptor axis-targeting (ARAT) agents in clinical data, but not in in vitro data. We investigated the clinical outcome of cabazitaxel chemotherapy after docetaxel according to use of ARAT agents. Patients and Methods: Prostate specific antigen (PSA) response, progression-free survival, and overall survival were compared between cases with and without prior use of ARAT agents in 74 Japanese patients with metastatic castration- resistant prostate cancer treated with cabazitaxel chemotherapy. Results: Background characteristics were comparable between patients with and without prior use of ARAT agents. PSA response, progression-free survival, and overall survival in cabazitaxel chemotherapy were comparable between patients with and without prior use of ARAT agents. Conclusion: No detrimental effects of prior ARAT agents on clinical outcome were observed for cabazitaxel chemotherapy in the postdocetaxel setting, suggesting that cabazitaxel can be expected to remain active even after ARAT agent therapy.

机译：背景/目的：新型紫杉烷Cabazitaxel已被证明在临床数据中雄激素受体轴靶向（ARAT）药物后发挥优异的抗癌作用，但不在体外数据中。我们根据Arat代理的使用，调查了多西紫杉醇后Cabazitaxel化疗的临床结果。患者和方法：比较患者的前列腺特异性抗原（PSA）反应，无进展生存和整体存活，在74名日本患者中使用Cabazitaxel化疗治疗的74名日本患者中的ARAT剂。结果：背景特征在患者之间进行了可比性，无需缺少ARAT剂。 Cabazitaxel化疗的PSA反应，无进展生存和整体存活率在患者之间进行了可比，患者术后和不使用ARAT剂。结论：在突发近速区环境中对Cabazitaxel化疗观察到前ARAT代理对临床结果的不利影响，表明甚至在ARAT代理治疗后，也可以预期卡扎特仍将保持活性。

著录项

来源
《Anticancer Research: International Journal of Cancer Research and Treatment》 |2020年第1期|共5页
作者
Shiota Masaki; Nakamura Motonobu; Yokomizo Akira; Tomoda Toshihisa; Sakamoto Naotaka; Seki Narihito; Hasegawa Shuji; Yunoki Takakazu; Harano Masahiko; Kuroiwa Kentaro; Eto Masatoshi;
展开▼
作者单位

Kyushu Univ Grad Sch Med Sci Dept Urol Fukuoka Japan;

Natl Hosp Org Kyushu Canc Ctr Dept Urol Fukuoka Japan;

Harasanshin Hosp Div Urol Fukuoka Japan;

Oita Prefectural Hosp Dept Urol Oita Japan;

Natl Hosp Org Kyushu Med Ctr Dept Urol Fukuoka Japan;

Kyushu Cent Hosp Dept Urol Fukuoka Japan;

Kitakyushu Municipal Med Ctr Dept Urol Kitakyushu Fukuoka Japan;

Japanese Red Cross Fukuoka Hosp Dept Urol Fukuoka Japan;

JCHO Kyushu Hosp Dept Urol Kitakyushu Fukuoka Japan;

Miyazaki Prefectural Miyazaki Hosp Dept Urol Miyazaki Japan;

Kyushu Univ Grad Sch Med Sci Dept Urol Fukuoka Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Abiraterone; androgen receptor; cabazitaxel; docetaxel; enzalutamide; prostate cancer;

机译：abiraatorone;雄激素受体;Cabazitaxel;Docetaxel;苯甲酸;前列腺癌;

相似文献

外文文献
中文文献
专利

1. Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel [J] . Shiota Masaki, Nakamura Motonobu, Yokomizo Akira, Anticancer Research: International Journal of Cancer Research and Treatment . 2020,第1期

机译：先前雄激素受体轴靶向剂在Cabazitaxel化疗后的预后影响多西紫杉醇
2. No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer [J] . Miyake Hideaki, Matsushita Yuto, Tamura Keita, International journal of clinical oncology . 2018,第3期

机译：对先前雄激素受体轴靶向剂对患者在转移阉割的前列腺癌患者的疗效没有显着影响。
3. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide [J] . Miyake Hideaki, Matsushita Yuto, Tamura Keita, Medical oncology . 2017,第12期

机译：先前雄激素受体轴靶向剂对转移阉割前列腺癌患者随后的多西紫杉醇临床活性的影响：AbiraTerone醋酸盐和依甲酰胺之间的比较评估
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Impact of Erythropoiesis Stimulating Agents on Survival and Risk of Venous Thromboembolism Among Patients with Colorectal Cancer Receiving Chemotherapy. [D] . Sato, Masayo. 2012

机译：红细胞生成刺激剂对接受化疗的结直肠癌患者生存率和静脉血栓栓塞风险的影响。
6. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer [O] . Takeo Kosaka, Hiroshi Hongo, Keitaro Watanabe, -1

机译：多西紫杉醇的患者年龄和既往治疗方式对去势抵抗性前列腺癌患者中卡巴他赛的疗效无明显影响
7. Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance [O] . Peng-Fei Zhang, Dan Xie, Qiu Li 2021

机译：Cabazitaxel在多西紫杉醇和雄激素信号抑制剂抗性后转移阉割前列腺癌的Cabazitaxel成本效果分析
8. Androgen receptor-based imaging agents for the prostate: Synthesis and tissue distribution studies with tritium and fluorine-18 labeled androgens [R] . Liu, A, Carlson, KE, Katzenellenbogen, JA, 1990

机译：基于雄激素受体的前列腺成像剂：用氚和氟-18标记的雄激素进行合成和组织分布研究

Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel

摘要

著录项

相似文献

相关主题

期刊订阅